{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-061936","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2025-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.917660+00:00","generated_at":"2026-05-18T09:07:21.349479+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Unicycive regains Nasdaq minimum bid price compliance after reverse split","bullets":["Regained compliance with Nasdaq minimum bid price of $1.00 per share.","Nasdaq notified the company on July 7, 2025, confirming compliance as of July 3, 2025.","Compliance achieved after a 1:10 reverse stock split effective June 20, 2025.","The matter is now closed by Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-061936","json":"https://secwatch.observer/filing/0001213900-25-061936.json","markdown":"https://secwatch.observer/filing/0001213900-25-061936.md","text":"https://secwatch.observer/filing/0001213900-25-061936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025061936/0001213900-25-061936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390025061936/ea0248322-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T09:07:21.349479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}